Rastilav Bahleda
Institut Gustave Roussy · 157 works · 2,308 citations · h-index 23
Top works
- Kidney Diseases Associated With Anti-Vascular Endothelial Growth Factor (VEGF)
- First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
- Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
- Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation
- A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
- Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy
- Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
- Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression
- TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
- Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven
- OA12.03 Activity of Crizotinib in MET or ROS1 Positive (+) NSCLC: Results of the AcSé Trial.
- Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells
- Bevacizumab-induced laryngeal necrosis
- Abstract B153: A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTOR inhibitor GDC-0980 administered once weekly (QW).
- Significant Antitumor Activity of E-3810, a Novel FGFR and VEGFR Inhibitor, in Patients With FGFR1 Amplified Breast Cancer
- Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors
- Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1–CREB1 fusion and ALK overexpression
- Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer
- Electrolyte disorders related to EGFR-targeting drugs
- Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma